The present invention pertains to the field of pharmaceutical and chemical engineering, and relates to a puerarin hydrate, the preparation method and use thereof. Specifically, said puerarin hydrate has a molecular formula of C21H20O9.n H2O, in which n is a value of 0.8-1.3. The present invention further relates to a pharmaceutical composition comprising said puerarin hydrate, and a method for the treatment of cardiovascular diseases or eye diseases. The puerarin hydrate of the present invention is more stable than puerarin without water of crystallization, convenient for storage and transportation, and has good fluidity at room temperature thereby easy for the manufacture of preparations.
